BriaCell Therapeutics (BCTX) shares BriaPro Q3 2025 interim results disclosure

Rhea-AI Filing Summary

BriaCell Therapeutics Corp. reported that its two-thirds owned subsidiary, BriaPro Therapeutics Corp., has filed unaudited condensed interim consolidated financial statements and a management’s discussion and analysis for the three-month period ended October 31, 2025 with securities regulators in British Columbia and Alberta. These BriaPro financial statements and the related discussion are attached to the report as Exhibits 99.1 and 99.2 and are incorporated by reference for informational purposes only. The company notes that this information is being furnished under Regulation FD and is not considered filed for liability purposes under U.S. securities laws.

false 0001610820 0001610820 2025-12-29 2025-12-29 0001610820 BCTX:CommonSharesNoParValueMember 2025-12-29 2025-12-29 0001610820 BCTX:WarrantsToPurchaseCommonSharesNoParValueMember 2025-12-29 2025-12-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 29, 2025

BRIACELL THERAPEUTICS CORP.

(Exact name of registrant as specified in its charter)

British Columbia A1		47-1099599
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

Suite 300 - 235 15th Street West Vancouver, BC V7T 2X1		V7T 2X1
(Address of principal executive offices)		(Zip Code)

(604) 921-1810

(Registrant’s telephone number, including area code)

Commission File No. 001-40101

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered under Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Shares, no par value		BCTX		The Nasdaq Stock Market LLC
Warrants to purchase common shares, no par value		BCTXW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On December 29, 2025, BriaPro Therapeutics Corp., a two-third (2/3) owned subsidiary of BriaCell Therapeutics Corp. (the “Company”), filed its unaudited condensed interim consolidated financial statements and management’s discussion and analysis for the three month period ended October 31, 2025, with the British Columbia Securities Commission and Alberta Securities Commission. A copy of the condensed interim consolidated financial statements and management’s discussion and analysis for the for the three month period ended October 31, 2025 are included as Exhibit 99.1 and Exhibit 99.2 to this Current Report on Form 8-K and are incorporated herein by reference.

The information furnished pursuant to this Item 7.01, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933 (the “Securities Act”) or the Exchange Act, regardless of any general incorporation language in such filings.

Item 9.01 Condensed interim financial statements and Exhibits

EXHIBIT INDEX

Exhibit No.
99.1		BriaPro Therapeutics Corp. Unaudited Condensed interim consolidated financial statements for the three month period ended October 31, 2025.
99.2		BriaPro Therapeutics Corp. Management’s Discussion and Analysis for the three month period ended October 31, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BRIACELL THERAPEUTICS CORP.
	/s/ William V. Williams
December 29, 2025	William V. Williams
	President and Chief Executive Officer

FAQ

What did BriaCell Therapeutics Corp. (BCTX) disclose in this 8-K?

BriaCell Therapeutics Corp. disclosed that its two-thirds owned subsidiary, BriaPro Therapeutics Corp., filed unaudited condensed interim consolidated financial statements and a management’s discussion and analysis for the three-month period ended October 31, 2025 with Canadian securities regulators. These documents are attached as Exhibits 99.1 and 99.2.

Which period do BriaPro Therapeutics Corp.’s financial statements cover?

The BriaPro Therapeutics Corp. unaudited condensed interim consolidated financial statements and management’s discussion and analysis cover the three-month period ended October 31, 2025.

Where were BriaPro Therapeutics Corp.’s interim filings made?

BriaPro Therapeutics Corp. filed its unaudited interim consolidated financial statements and management’s discussion and analysis with the British Columbia Securities Commission and the Alberta Securities Commission.

How is BriaPro Therapeutics Corp. related to BriaCell Therapeutics Corp. (BCTX)?

BriaPro Therapeutics Corp. is described as a two-third (2/3) owned subsidiary of BriaCell Therapeutics Corp.

Are the BriaPro financial statements considered filed under U.S. securities laws?

No. The company states that the information provided under Item 7.01, including Exhibits 99.1 and 99.2, is being furnished, not filed, and is therefore not subject to the liabilities of Section 18 of the Securities Exchange Act of 1934 or automatically incorporated into other Securities Act or Exchange Act filings.

What exhibits are included with BriaCell Therapeutics Corp.’s 8-K?

The exhibits are: 99.1 BriaPro Therapeutics Corp. unaudited condensed interim consolidated financial statements for the three-month period ended October 31, 2025; 99.2 BriaPro Therapeutics Corp. management’s discussion and analysis for the same period; and 104 the cover page interactive data file embedded in the Inline XBRL document.

Does this 8-K report any major transactions or earnings for BriaCell (BCTX)?

No. The report focuses on Regulation FD disclosure related to BriaPro’s interim financial statements and discussion. It does not describe major transactions or provide separate earnings figures for BriaCell in this text.